VIRX logo

Viracta Therapeutics, Inc. Common Stock


VIRX: Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.


Show VIRX Financials

Consumer Interest
SEC Filings

Recent trades of VIRX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by VIRX's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods of treating virally associated cancers with histone deacetylase inhibitors Mar. 23, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of VIRX in WallStreetBets Daily Discussion


Recent insights relating to VIRX

CNBC Recommendations

Recent picks made for VIRX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in VIRX

Corporate Flights

Flights by private jets registered to VIRX